Systagenix Wound Management Limited, a leading name in the wound care industry, is headquartered in Great Britain. Founded in 2008, the company has established itself as a key player in the development of advanced wound management solutions, focusing on innovative products that enhance healing and improve patient outcomes. With a strong presence in Europe and North America, Systagenix offers a range of unique products, including advanced dressings and bioactive therapies, designed to address various wound types. Their commitment to research and development has led to significant milestones, positioning them as a trusted partner in healthcare. Recognised for their quality and efficacy, Systagenix continues to set industry standards, making substantial contributions to the field of wound management.
How does Systagenix Wound Management Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Systagenix Wound Management Limited's score of 66 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Systagenix Wound Management Limited, headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of 3M Company, and any climate commitments or emissions data may be inherited from this parent organization. As part of its corporate family relationship with 3M Company, Systagenix is aligned with several climate initiatives, including the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from 3M at a third-level relationship. However, specific reduction targets or achievements for Systagenix itself are not detailed in the available information. While Systagenix Wound Management Limited does not provide its own emissions data or reduction targets, it is important to note that the company is part of a broader commitment to sustainability and climate action through its association with 3M Company. This relationship may influence its future climate strategies and emissions reporting.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 157,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
| Scope 2 | 111,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | 2,229,960,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 
Systagenix Wound Management Limited's Scope 3 emissions, which increased by 9% last year and decreased by approximately 23% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Systagenix Wound Management Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.